A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome

References

• Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434–2438.
   PubMed Web of Science ®Google Scholar
• Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082.
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47.
   PubMed Web of Science ®Google Scholar
• Holtkamp DE, Greslin JG, Root CA, Lerner LJ. Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene. Proc Soc Exp Biol Med 1960; 105: 197–201.
   PubMed Web of Science ®Google Scholar
• Hughes E, Collins J, Vanderkerckhove P, Lilford R. Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea. Cochrane Database Syst Rev 2000; CD000056.
   Google Scholar
• Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997; 3: 359–365.
   PubMed Web of Science ®Google Scholar
• LehmannJM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953–12956.
   PubMed Web of Science ®Google Scholar
• Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2694–2698.
   PubMed Web of Science ®Google Scholar
• DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83: 1454–1460.
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004; 82: 661–665.
   PubMed Web of Science ®Google Scholar
• Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562–566.
   PubMed Web of Science ®Google Scholar
• Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007; 196: 402.e1–10; discussion 402.e10.
   Google Scholar
• Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 2006; 85: 428–435.
   PubMed Web of Science ®Google Scholar
• LIAO Lin, TIAN Yong-jie, ZHAO Jia-jun, XIN Ying, XING Hai-yang, DONG Jian-jun. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chin Med J 2011;124:714–718.
   PubMed Web of Science ®Google Scholar
• CataldoNA, Abbasi F, McLaughlin TL, Basina M, Fechner PY, Giudice LC and Reaven GM Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Rep 2006; 29: 109–120.
   Google Scholar
• Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82: 893–902.
   PubMed Web of Science ®Google Scholar
• Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 624–629.
   PubMed Web of Science ®Google Scholar
• Ortega-GonzalezC, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga-Troncoso G and Parra A. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1360–1365.
   PubMed Web of Science ®Google Scholar
• SepilianV and Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005; 90: 60–65.
   PubMed Web of Science ®Google Scholar
• RaskinP, Rappaport EB, Cole ST, Yan Y, Patwardhan R and Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278–284.
   PubMed Web of Science ®Google Scholar
• LebovitzHE, Dole JF, Patwardhan R, Rappaport EB and Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280–288.
   PubMed Web of Science ®Google Scholar
• Evanthia Diamanti-Kandarakis, Chryssa Kouli, Krystallenia Alexandraki and Giovann Spina Failure of Mathematical Indices to Accurately Assess Insulin Resistance in Lean, Overweight, or Obese Women with Polycystic Ovary Syndrome. J Clin Endocrin& Metabol 2004; 89: 1273–1276
   Google Scholar
• Ronald L Krall. Cardiovascular safety of rosiglitazone. The Lancet, 2007; 369: 1995–1996
   Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. The Lancet 2009; 373: 2125– 2135.
   PubMed Web of Science ®Google Scholar
• SongJ, Knepper MA, Hu X, Verbalis JG and Ecelbarger CA. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004; 308: 426–433.
   PubMed Web of Science ®Google Scholar
• ShimizuH, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I and Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998; 21: 1470–1474.
   PubMed Web of Science ®Google Scholar
• Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 2004; 18: 619–621.
   PubMed Web of Science ®Google Scholar
• Kalyoncu NI, Yaris F, Ulku C, Kadioglu M, Kesim M, Unsal M, Dikici M, Yaris E. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 2005; 19: 563–564.
   PubMed Web of Science ®Google Scholar
• Haddad GF, Jodicke C, Thomas MA, Williams DB, Aubuchon M. Case series of rosiglitazone used during the first trimester of pregnancy. Reprod Toxicol 2008; 26: 183–184.
   PubMed Web of Science ®Google Scholar
• Mitkov M, Pehlivanov B, Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126: 93–98.
   PubMed Web of Science ®Google Scholar